Data sharing in and after COVID, with Takeda’s Anne Heatherington: a BioCentury podcast

Among the barriers broken by biopharmas during COVID-19 is the concept of data sharing, an idea far from standard practice in the industry, gaining life due to the gravity and urgency of the pandemic.

Proponents contend that if companies share clinical data -- in particular patient-level clinical data -- they can change the course and speed of bringing therapies and vaccines to approval...